Hansen et al [10] have shown that etoposide resistance in SCLC cells is positively correlated with RAD51 levels and have suggested that RAD51 is a potential target to improve etoposide efficacy in treatment of SCLC. This evidence concerns the gene RAD51 and small cell lung carcinoma.